Qurient Co (115180.KQ) Stock Price

Qurient Co Price

CLOSED
14,500.00
​
Market closed

Revenue has compounded at 37.2% per year over the past 11 years to 6.98 B KRW. Qurient Co's net margin stands at -430.4%, up from -467.6% several years earlier.

Qurient Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Qurient Co business model & stock analysis

Qurient Co., Ltd. develops novel therapeutics with two main program phases. The development phase includes Q203 for drug-resistant tuberculosis, Q301 for atopic dermatitis, and Q701 for drug-resistant cancer and anti-cancer immunotherapy. The research phase focuses on five lipoxygenase (5LO) inhibitor asthma medicines and a cyclin dependent kinase 7 (CDK7) inhibitor cancer drug. The company generates revenue through these therapeutic programs, targeting pharmaceutical companies and healthcare providers seeking innovative treatments for resistant diseases and chronic conditions. Qurient's products are developed for specific medical needs, with Q203 addressing tuberculosis that resists standard drugs, Q301 treating skin inflammation conditions, and Q701 enhancing cancer immunotherapy. The research phase programs aim to advance asthma and cancer treatments through novel inhibitors. Pharmaceutical companies and healthcare providers purchase these therapies to address unmet medical needs in their markets. The company's revenue streams come from the development and potential commercialization of Q203, Q301, Q701, and the research phase programs. These programs target segments including tuberculosis treatment, dermatology, oncology, and respiratory diseases. Pharmaceutical firms and healthcare institutions are the primary buyers of Qurient's therapeutic solutions for drug-resistant conditions and advanced treatment options.

Frequently asked questions about Qurient Co

Converted at the current exchange rate, the Qurient Co share trades at 9.87 EUR (14,500.00 KRW).

The revenue cannot currently be calculated for Qurient Co.

The profit cannot currently be calculated for Qurient Co.

The P/E ratio cannot be calculated for Qurient Co at the moment.

The P/S cannot be calculated for Qurient Co currently.

The Eulerpool Quality Score for Qurient Co is 3/10.

The ISIN of Qurient Co is KR7115180002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Qurient Co is 115180.KQ. The ticker symbol is used to trade Qurient Co shares on the stock exchange.

Fair ValueTerminal
11,890.00 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website qurient.com
Country
South Korea
Currency
KRW
Initial public offering
Feb 29, 2016
ISIN
KR7115180002
Cusip
Y7S695104
Market capitalization
454.57 B KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
13.35
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-64.84 %
Last updated Nov 17, 2026, 3:43 AM

Qurient Co Peer Group

Qurient Co FIGI

115180:KS · BBG0089B97N8115180:KQ · BBG00BCJ8PY9

All fundamentals and in-depth analysis of Qurient Co

Our stock analysis for Qurient Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Qurient Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.